Prior to testing of individual target mutant epitopes, identified by tumor exome sequencing, T-cell recognition was gauged using a broad panel of antigens associated with common viral pathogens (e.g. CMV, EBV, Flu), tumor–associated antigens (e.g. NY-ESO- 1, Melan-A/MART-1, survivin, mesothelin). Here, BIRC5 is linked to neoplasm.